A newsletter for students, faculty, staff, alumni and friends
May 11, 2018
UMES professor and alum secure U.S. Patent for new drug
She is the second faculty A medical research project member in the past 20 months Dr. Patrice Jackson-Ayotunde to be a primary recipient of a U.S. began seven years ago has earned Patent assigned exclusively to UMES. the University of Maryland Eastern Engineering professor Yuanwei Jin Shore pharmacy professor a U.S. earned one in mid-2016 for his Patent. “smart structure” sensing device Jackson-Ayotunde received capable of detecting metal fatigue. word April 3 from the U.S. Patent “I was overjoyed,” Jacksonand Trademark Office that it Ayotunde said, adding “I could feel a officially acknowledges her large weight had been lifted.” “It was discovery of a chemical formula for gratifying to know that a lot of hard new medication to treat epilepsy. work was being recognized.” Epilepsy is a chronic An estimated one in 26 neurological disorder characterized people will develop epilepsy in by recurring seizures, which can their lifetime, according to the be debilitating. Some patients Epilepsy Foundation. Worldwide, experience multiple episodes daily. Dr. Tawes Harper, a 2013 UMES pharmacy program graduate, and an estimated 65 million people have Dr. Patrice Jackson-Ayotunde, his mentor in a research project, Jackson-Ayotunde, an associate were awarded a U.S. Patent for a new drug to treat epilepsy. been diagnosed with the condition. professor in the School of Pharmacy How quickly her idea for a and Health Professions, shares new medication can make its way to the marketplace depends on whether discovery credit with Dr. Tawes Harper, a 2013 UMES pharmacy program pharmaceutical companies see promise in it and are willing to invest millions graduate who assisted her with the research.
PATENT / continued on page 2
Dr. Sean Vasaitis, an assistant professor of pharmaceutical sciences, New Hope for Prostate has the distinction of being the only current member of the University of Eastern Shore faculty with two U.S. Patents to his credit. Cancer and Other Diseases Maryland The latest came in early February for the development and use of “novel compounds (that) are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional androgen receptors.” Vasaitis is part of a team that includes five other long-time collaborators originally at the University of Maryland School of Medicine who earned a previous patent regarding this technology breakthrough in 2016. “It’s been very rewarding work, and something I take quite seriously,” said Vasaitis, a 1996 UMES alumnus and the pharmacy school’s Interim Assistant Dean for Student Affairs. His co-inventors listed on both patents are: Dr. Vincent C.O. Njar (lead inventor), Lalji K. Gediya, Puranik Purushottamachar, Abhijit Godbole and Andrew Kwegyir-Afful. The research team has additional patents pending in more than 30 countries around the world. Vasaitis, who joined the UMES faculty in 2010, said the research is motivated by the sobering statistic that “prostate cancer is the (nation’s) second-leading cause of cancer death in men, with a one-in-nine lifetime risk of being diagnosed with the disease.” Vasaitis said he and fellow researchers focus on finding compounds capable of disrupting the action of multiple pathways in the body that fuel prostate cancer growth. “Prostate cancer progression is often driven by natural chemical messengers called androgens,” he said. “Androgens
INSIDE
NEW HOPE / continued on page 5
Page 2
Rural Health Summitt
Page 3
Golf Program’s New Indoor Venue Faculty Member Recognized Peace Corps Promote Program
Page 4
Criminal Justice Week A Success 5K Raises Funds for Epilepsy
Page 5
Aviation Student Attends Air Show In Germany Dietetic Students Attend Professional Event
Page 6
Athletics Department Recognizes Standouts
Page 7
Student Society Exhibits Bell Throws First Pitch OC Art Show Archaeology Dig at UMES Tractor Day Clinic Offers Tie Techniques
Page 8
A&E Calendar Tom Joyner Foundation Hytche Legacy